TORONTO, Oct. 05, 2026 (GLOBE NEWSWIRE) — (TSX: SPFD) Mulvihill Enhanced Split Preferred Share ETF has declared a monthly cash distribution in the amount of $0.08333 per unit, payable on November 6, 2026 to unitholders of record on October 30, 2026.

For further information, please contact Investor Relations at 416.681.3966, toll free at 1.800.725.7172, email at info@mulvihill.com or visit www.mulvihill.com.

John Germain, Senior VP & CFO Mulvihill Capital Management Inc.
  25 King Street West
  Commerce Court North
  Suite 2110, Box 48
  Toronto, Ontario, M5L 1A1
   

Commissions, trailing commissions, management fees and expenses all may be associated with exchange traded funds (ETFs). Please read the prospectus before investing. ETFs are not guaranteed, their values change frequently, and past performance may not be repeated. There are risks involved with investing in ETFs. Please read the prospectus for a complete description of risks relevant to ETFs. Investors may incur customary brokerage commissions in buying or selling ETFs.

TORONTO, Oct. 05, 2026 (GLOBE NEWSWIRE) — (TSX: CBNK) Mulvihill Canadian Bank Enhanced Yield ETF has declared a monthly cash distribution in the amount of $0.12 per unit, payable on November 6, 2026, to unitholders of record on October 30, 2026.
  
For further information, please contact Investor Relations at 416.681.3966, toll free at 1.800.725.7172, email at info@mulvihill.com or visit www.mulvihill.com.

John Germain, Senior Vice-President & CFO Mulvihill Capital Management Inc.
25 King Street West
Commerce Court North
Suite 2110, Box 48
Toronto, Ontario, M5L 1A1
   

Commissions, trailing commissions, management fees and expenses all may be associated with investment funds. Please read the prospectus before investing. Investment funds are not guaranteed, their values change frequently and past performance may not be repeated.

TORONTO, Oct. 05, 2026 (GLOBE NEWSWIRE) — (TSX: MPY) Mulvihill Premium Yield has declared a monthly cash distribution for its ETF Class in the amount of $0.07 per unit, payable on November 6, 2026 to unitholders of record on October 30, 2026.

For further information, please contact Investor Relations at 416.681.3966, toll free at 1.800.725.7172, email at info@mulvihill.com or visit www.mulvihill.com.

John Germain, Senior Vice-President & CFO
 
Mulvihill Capital Management Inc.
25 King Street West
Commerce Court North
Suite 2110, Box 48
Toronto, Ontario, M5L 1A1
 
   

Commissions, trailing commissions, management fees and expenses all may be associated with investment funds. Please read the prospectus before investing. Investment funds are not guaranteed, their values change frequently and past performance may not be repeated.

TORONTO, Oct. 05, 2026 (GLOBE NEWSWIRE) — (TSX: PGIC; PGIC.PR.A) Premium Global Income Split Fund has declared monthly distributions payable on October 30, 2026 to shareholders of record on October 15, 2026 in the following amounts per share:

Share Class Ticker Amount Per Share
Class A Shares PGIC $0.08000
Preferred Shares PGIC.PR.A $0.06250

To the extent that any portions of the distributions are ordinary taxable dividends and not capital gain dividends, they are eligible dividends.

For further information, please contact Investor Relations at 416.681.3966, toll free at 1.800.725.7172, email at info@mulvihill.com or visit www.mulvihill.com.

John Germain, Senior Vice-President & CFO Mulvihill Capital Management Inc.
25 King Street West
Commerce Court North
Suite 2110, Box 48
Toronto, Ontario, M5L 1A1
   

Commissions, trailing commissions, management fees and expenses all may be associated with investment funds. Please read the prospectus before investing. Investment funds are not guaranteed, their values change frequently and past performance may not be repeated.

ORIC-259 is a potential first-in-class small molecule mRNA degrader targeting CIP2A, a previously undruggable target

Cancer Research UK to fully fund, sponsor, design, and execute CTA-enabling studies and Phase 1/2 clinical development

ORIC retains exclusive option to reacquire rights to ORIC-259 following Phase 1/2 data

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 05, 2026 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing and commercializing treatments that address mechanisms of therapeutic resistance, today announced an agreement with Cancer Research UK, one of the world’s largest funders of cancer research, to advance a potential first-in-class CIP2A-targeted therapy into clinical development.

Under the agreement, Cancer Research UK’s Centre for Drug Development (CDD) will fully fund, sponsor, design, and execute CTA-enabling studies and early clinical development of ORIC-259 for patients with cancer. ORIC retains an option to reacquire rights to ORIC-259 following Phase 1/2 data, with Cancer Research UK eligible to receive downstream milestone payments and royalties.

Cancerous Inhibitor of PP2A (CIP2A) is a protein that contributes to the development and progression of many cancer types due to its role in protein phosphorylation, mitosis, and DNA damage response. ORIC-259 is a potent, selective, orally bioavailable small molecule degrader of CIP2A mRNA. This potential first-in-class mRNA degrader is designed to modify mRNA splicing to incorporate a premature stop codon, leading to mRNA degradation and loss of CIP2A protein, which is critical for cell proliferation and survival of cancers with homologous recombination deficiency (HRD). Promising preclinical data highlight robust antitumor activity in PARP inhibitor sensitive and resistant settings, indicating broad potential for patients with HRD cancers, and supports the path to clinical development for ORIC-259.

“We are excited to partner with Cancer Research UK to advance ORIC-259, a potential first-in-class CIP2A-targeted therapy, into the clinic,” said Lori Friedman, PhD, chief scientific officer. “Cancer Research UK’s proven expertise and capabilities in developing innovative cancer therapies make it an ideal partner for the program, while this structure allows us to remain disciplined in allocating our internal resources to our late-stage clinical pipeline.”

“ORIC-259 represents an innovative approach to targeting CIP2A, a protein with significant potential in cancer but one that has proven difficult to drug,” said Lars Erwig, Director of the CDD. “We share ORIC’s mission to overcome treatment resistance in cancer, and we look forward to applying our expertise to explore new treatment options for patients.”

About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) rinzimetostat, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) enozertinib, a brain-penetrant inhibitor targeting EGFR exon 20 insertion and EGFR atypical mutations, being developed for NSCLC. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on X or LinkedIn.

About Cancer Research UK’s Centre for Drug Development
Cancer Research UK has an impressive record of developing novel treatments for cancer. The Cancer Research UK Centre for Drug Development has been pioneering the development of new cancer treatments for 30 years. It has completed over 170 clinical trials designed to explore potential new anti-cancer agents in patients. Six of these new agents have made it to market, including temozolomide for brain cancer, abiraterone for prostate cancer and rucaparib for ovarian cancer. www.cruk.org.uk/cdd

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, statements regarding a potential first-in-class CIP2A-targeted therapy; the potential benefits of ORIC-259 and the agreement with Cancer Research UK; ORIC’s option to reacquire rights to ORIC-259 following Phase 1/2 data; and statements by the director of the CDD and the company’s chief scientific officer. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. The forward-looking statements contained herein are based upon ORIC’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those projected in any forward-looking statements due to numerous risks and uncertainties, including but not limited to: risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics; ORIC’s or Cancer Research UK’s ability to develop, initiate or complete preclinical studies and clinical trials for, obtain approvals for and commercialize ORIC-259; changes in ORIC’s or Cancer Research UK’s plans to develop ORIC-259; the potential for preclinical studies or clinical trials of ORIC-259 to differ from prior preclinical, initial, interim, preliminary or expected results; negative impacts of health emergencies, economic instability or international conflicts on ORIC’s or Cancer Research UK’s operations, including preclinical studies and clinical trials; the risk of the occurrence of any event, change or other circumstance that could give rise to the termination of the agreement with Cancer Research UK; the potential market for ORIC-259, and the progress and success of competing therapeutics currently available or in development; ORIC’s ability to raise any additional funding it will need to continue to pursue its business and product development plans; regulatory developments in the United States and foreign countries; ORIC’s reliance on third parties, including contract manufacturers and contract research organizations; ORIC’s ability to obtain and maintain intellectual property protection for ORIC-259 and its other product candidates; the loss of key scientific or management personnel; competition in the industry in which ORIC operates; general economic and market conditions; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in ORIC’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on August 3, 2026, and ORIC’s future reports to be filed with the SEC. These forward-looking statements are made as of the date of this press release, and ORIC assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.

Contact:
Dominic Piscitelli, Chief Financial Officer
dominic.piscitelli@oricpharma.com
info@oricpharma.com

TORONTO, Oct. 05, 2026 (GLOBE NEWSWIRE) — (TSX: MBNK) Mulvihill Canadian Bank ETF has declared a monthly cash distribution in the amount of $0.05 per share, payable on November 6, 2026, to shareholders of record on October 30, 2026.
  
For further information, please contact Investor Relations at 416.681.3966, toll free at 1.800.725.7172, email at info@mulvihill.com or visit www.mulvihill.com.

John Germain, Senior Vice-President & CFO Mulvihill Capital Management Inc.
25 King Street West
Commerce Court North
Suite 2110, Box 48
Toronto, Ontario, M5L 1A1
   

Commissions, trailing commissions, management fees and expenses all may be associated with investment funds. Please read the prospectus before investing. Investment funds are not guaranteed, their values change frequently and past performance may not be repeated.

TORONTO, Oct. 05, 2026 (GLOBE NEWSWIRE) — (TSX: PFRD) Mulvihill Split Preferred Share ETF has declared a monthly cash distribution in the amount of $0.11667 per share, payable on November 6, 2026, to shareholders of record on October 30, 2026.

For further information, please contact Investor Relations at 416.681.3966, toll free at 1.800.725.7172, email at info@mulvihill.com or visit www.mulvihill.com.

John Germain, Senior Vice-President & CFO Mulvihill Capital Management Inc.
25 King Street West
Commerce Court North
Suite 2110, Box 48
Toronto, Ontario, M5L 1A1


Commissions, trailing commissions, management fees and expenses all may be associated with investment funds. Please read the prospectus before investing. Investment funds are not guaranteed, their values change frequently and past performance may not be repeated.

RED BANK, N.J., Oct. 05, 2026 (GLOBE NEWSWIRE) — OceanFirst Financial Corp. (NASDAQ: OCFC) (the “Company”), the holding company for OceanFirst Bank N.A. (the “Bank”), today announced that it will release its third quarter 2026 financial results after the market close on Tuesday, October 27, 2026. Management will host a conference call to discuss the results at 8:00 a.m. Eastern Time on Wednesday, October 28, 2026.

To participate by phone, dial 1-833-461-5787 (U.S. toll-free) and enter meeting ID 545140997. A live, listen-only webcast will be available on the Company’s investor relations website at https://ir.oceanfirst.com/ or directly at https://events.q4inc.com/attendee/545140997. Webcast participants should register at least fifteen minutes before the call. A replay of the webcast will be available at the same link after the call.

OceanFirst Financial Corp.’s subsidiary, OceanFirst Bank N.A., founded in 1902, is a $23 billion regional bank serving business and retail customers throughout New Jersey, New York, Long Island, and the major metropolitan areas from Massachusetts through Virginia. OceanFirst Bank delivers commercial and residential financing, treasury management, trust and asset management, and deposit services and is one of the largest and oldest community-based financial institutions headquartered in New Jersey. To learn more about OceanFirst, please visit us at www.oceanfirst.com.

Forward-Looking Statements

In addition to historical information, this press release contains certain forward-looking statements within the meaning of the federal securities laws, which are based on certain assumptions and describe future plans, strategies and expectations of the Company. Forward-looking statements may be identified by the use of the words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “expect,” “anticipate,” “believe,” “seek,” “strategy,” “future,” “opportunity,” “may,” “could,” “target,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” or similar expressions that predict or indicate future events or trends or that are not statements of historical matters, although not all forward-looking statements contain such identifying words. These statements are based on various assumptions, whether or not identified in this document, and on the current expectations of the Company’s management and are not predictions of actual performance, and, as a result, are subject to risks and uncertainties. These forward-looking statements are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict, may differ from assumptions and many are beyond the control of the Company. The forward-looking statements are intended to be subject to the safe harbor provided by Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995. Factors that could have a material adverse effect on the operations of the Company and its subsidiaries include, but are not limited to: changes in interest rates, inflation, general economic conditions, including potential recessionary conditions, levels of unemployment in the Company’s lending area, real estate market values in the Company’s lending area, potential goodwill impairment, natural disasters, potential increases to flood insurance premiums, the current or anticipated impact of military conflict, terrorism or other geopolitical events, the imposition of tariffs or other domestic or international governmental policies, trade restrictions and retaliatory measures impacting the Company’s borrowers and the broader economy, the effects of a potential future federal government shutdown, debt ceiling impasses or fiscal uncertainty, the level of prepayments on loans and mortgage-backed securities, legislative/regulatory changes, monetary and fiscal policies of the U.S. Government, including policies of the U.S. Treasury and the Board of Governors of the Federal Reserve System, the quality or composition of the loan or investment portfolios, demand for loan products, deposit flows, the availability of low-cost funding, changes in liquidity, including the size and composition of the Company’s deposit portfolio and the percentage of uninsured deposits in the portfolio, changes in capital management and balance sheet strategies and the ability to successfully implement such strategies, competition, demand for financial services in the Company’s market area, our ability to enter into new markets and capitalize on growth opportunities, the adequacy of and changes in the economic assumptions and methodology for computing the allowance for credit losses, availability of capital, competition, our ability to maintain and increase market share and control expenses, changes in investor sentiment and consumer spending, borrowing and savings habits, changes in accounting principles, risks associated with cybersecurity threats, data breaches, ransomware attacks, or other failures in the Company’s operational or security systems and infrastructure, including the risks arising from the Company’s dependence on third-party service providers and vendors, the failure to maintain current technologies and the operational risks associated with the adoption of artificial intelligence and other emerging technologies, failure to retain or attract employees, the impact of pandemics on our operations and financial results and those of our customers and the Bank’s ability to successfully integrate acquired operations. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of OceanFirst’s Annual Report on Form 10-K for the year ended December 31, 2025, and other documents filed by OceanFirst from time to time with the U.S. Securities and Exchange Commission (the “SEC”). The Company does not undertake, and specifically disclaims any obligation, to publicly release the result of any revisions that may be made to any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

Investor Relations Inquiries:
OceanFirst Financial Corp.
Alfred Goon
SVP Corporate Development and Investor Relations
investorrelations@oceanfirst.com

Company Contact:

Patrick S. Barrett
Chief Financial Officer
OceanFirst Financial Corp.
1.888.623.2633 ext. 27507
Email: pbarrett@oceanfirst.com

ANNOUNCEMENT NO. 318
5 October 2026

Pursuant to section 30 of the Danish Capital Markets Act, notice is hereby given that BlackRock, Inc. has notified ChemoMetec that, on 29 September 2026, BlackRock, Inc. increased its voting rights attached to shares in ChemoMetec to 15.08%, thereby exceeding the 15% threshold under section 38 of the Danish Capital Markets Act.

BlackRock, Inc.’s position at that time was as follows:

  • Voting rights attached to shares: 15.08%
  • Voting rights through financial instruments: 0.00%
  • The total of both: 15.08%

BlackRock, Inc. has previously notified the following:

28 August 2026

BlackRock Investment Management (UK) Limited, which is part of the BlackRock Group, exceeded the 10% threshold under section 38 of the Danish Capital Markets Act and the 10% threshold for its total position under section 40 of the Danish Capital Markets Act.

BlackRock, Inc.’s total position on the same date was as follows:

  • Voting rights attached to shares: 12.98%
  • Voting rights through financial instruments: 0.05%
  • The total of both: 13.03%

At the same time, BlackRock Investment Management (UK) Limited held a total position of 10.04%, comprising 10.04% in voting rights attached to shares and 0.00% through financial instruments.

29 April 2026

BlackRock Investment Management (UK) Limited, which is part of the BlackRock Group, fell below the 10% threshold under section 40 of the Danish Capital Markets Act.

BlackRock, Inc.’s total position on the same date was as follows:

  • Voting rights attached to shares: 12.77%
  • Voting rights through financial instruments: 0.15%
  • The total of both: 12.92%

At the same time, BlackRock Investment Management (UK) Limited held a total position of 9.94%, comprising 9.79% in voting rights attached to shares and 0.15% through financial instruments.

22 April 2026

BlackRock Investment Management (UK) Limited, which is part of the BlackRock Group, fell below the 10% threshold under section 38 of the Danish Capital Markets Act.

BlackRock, Inc.’s total position on the same date was as follows:

  • Voting rights attached to shares: 12.94%
  • Voting rights through financial instruments: 0.18%
  • The total of both: 13.12%

At the same time, BlackRock Investment Management (UK) Limited held a total position of 10.15%, comprising 9.99% in voting rights attached to shares and 0.16% through financial instruments.

Additional Information

Martin Helbo Behrens, CEO
Tel.: (+45) 81 10 06 80 

Phillip Massie Price, CFO
Tel.: (+45) 81 10 06 80 

About ChemoMetec A/S

ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements. ChemoMetec’s instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide. ChemoMetec’s customers include some of the world’s leading pharmaceutical companies.

ChemoMetec was founded in 1997 and is listed on Nasdaq OMX Copenhagen. For further information, go to www.chemometec.com.

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/

TORONTO, Oct. 05, 2026 (GLOBE NEWSWIRE) — PesoRama Inc. (TSXV:PESO) (OTC:PSSOF) (FSE:ZE6) (“PesoRama” or the “Company”), a Canadian company operating dollar stores in Mexico under the JOi DOLLAR PLUS brand, is pleased to announce that it has entered into an agreement with Canaccord Genuity Corp., as lead underwriter and sole bookrunner on behalf of itself and a syndicate of underwriters (collectively, the “Underwriters”), in connection with a “bought deal” public offering of 41,667,000 common shares of the Company (the “Offered Shares”) at a price of C$0.60 per Offered Share (the “Offering Price”) for gross proceeds of C$25,000,200 (the “Offering”).

The Company has also granted the Underwriters an option (the “Over-Allotment Option”) exercisable, in whole or in part, at any time and from time to time, within 30 days after the closing of the Offering, to purchase up to that number of additional Offered Shares at the Offering Price equal to 15% of the number of Offered Shares issued pursuant to the Offering.

The net proceeds of the Offering are expected to be used to continue store expansion of the Company’s JOi DOLLAR PLUS chain across Mexico, as well as general working capital purposes.

The Offering will be completed pursuant to an underwriting agreement to be entered into by the Company and the Underwriters. The Common Shares will be offered by way of a prospectus supplement (the “Prospectus Supplement”) to the Company’s short form base shelf prospectus dated September 23, 2026 to be filed in all provinces of Canada, other than Quebec. The Prospectus Supplement will contain important information about the Offering and will be filed within two business days. The Offered Shares may also be offered by way of private placement in the United States and in offshore jurisdictions as agreed to between the Company and the Underwriters.

The Offering is anticipated to close on or about October 14, 2026 (the “Closing Date”), or such later date as the Underwriters and the Company may determine. The closing is subject to certain conditions including, but not limited to, the receipt of all necessary regulatory and other approvals, including the approval of the TSX Venture Exchange (the “TSXV”).

The Company has agreed to pay to the Underwriters a cash commission equal to 6% of the gross proceeds of the Offering. In addition, the Company has agreed to issue to the Underwriters compensation warrants of the Company to acquire in aggregate the number of Common Shares equal to 6% of the number of Common Shares sold under the Offering. Each compensation warrant will be exercisable for a period of 24 months following the Closing Date at an exercise price equal to the Offering Price. A reduced commission shall be payable in respect of Offered Shares sold to purchasers on a president’s list.

This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful, including any of the securities in the United States of America. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “1933 Act”) or any state securities laws and may not be offered or sold within the United States or to, or for account or benefit of, U.S. Persons (as defined in Regulation S under the 1933 Act) unless registered under the 1933 Act and applicable state securities laws, or an exemption from such registration requirements is available.

The Offering will be made in all provinces of Canada, other than Quebec, under the Prospectus Supplement, on a private placement basis in the United States to qualified institutional buyers pursuant to Rule 144A under the 1933 Act, and internationally pursuant to applicable private placement exemptions.

Investors should read the Prospectus Supplement before making an investment decision. Access to the Prospectus Supplement and any amendments thereto is provided, and delivery thereof will be satisfied, in accordance with securities legislation relating to procedures for providing access to a prospectus supplement, a base shelf prospectus and any amendment to such documents.

About PesoRama Inc.

PesoRama Inc. is a Mexican value retailer that currently operates a chain of stores in Mexico under the brand name “JOi DOLLAR PLUS.” PesoRama’s stores offer a broad range of everyday household products, seasonal goods, and pet supplies at affordable prices. The Company’s mission is to become Mexico’s premier dollar store chain, targeting expansion to 500+ locations across Mexico.

For further information please contact:

Rahim Bhaloo
Founder, CEO & Chairman
rahim@rahimbhaloo.com
416-816-3291

Eduardo Fernandez
CFO
eduardo.fernandez@joi.mx
+52 331-862-7856

Cautionary Note

This press release contains “forward-looking information” within the meaning of applicable securities laws, including, among other things, statements regarding the completion of the Offering, the Closing Date and the intended use of proceeds of the Offering. While the Company believes that the expectations reflected in this forward-looking information are reasonable, undue reliance should not be placed on them because the Company can give no assurance that they will prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements, including due to changes in consumer behaviour, general economic factors, the ability of the Company to execute its strategies, the availability of capital and the risk factors which are discussed in greater detail in the “Risk Factors” section of the Company’s annual information form for the year ended January 31, 2026 and filed under the Company’s profile on www.sedarplus.ca. The statements in this press release are made as of the date of this release. PesoRama undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of PesoRama, its securities, or its financial or operating results (as applicable).

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.